Clinical Trials Logo

Clinical Trial Summary

Seasonal influenza is a frequent disorder with high impact on morbidity and mortality and significant burden on healthcare-related cost. In France, the 2018-2019 flu epidemic has led to 13,100 all-cause death including 9,900 death directly related to the viral infection.

As cross-transmission of influenza is responsible for nosocomial outbreaks, preventing transmission of infectious agents in healthcare settings is a major issue. If vaccination of patients and healthcare givers remains cornerstone, control procedures are mandatory. Therefore patients admitted with influenza require isolation precautions including admission in a single room and protective measures. Based on experts advise, isolation is currently recommended for 5 to 8 days. Duration of isolation depends on immune status and antiviral therapy. However, during periods of epidemic, every hospital room is valuable and each ressource has to be tightly used. Risk of contamination is related to the presence of influenza in the upper airways. To the Promoteur 's knowledge, presence of influenza in the upper airways has not been studied in patients receiving oseltamivir. The question is : Do duration of isolation in patients admitted with flu decreas when they are treated with antiviral therapy. To answer this question The Promoteur would aim to determine influenza carriage in the upper airways in in-patients treated by olsetamivir.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04515446
Study type Interventional
Source Centre Hospitalier Universitaire de Nice
Contact Olivia KEITA-PERSE, MD
Phone +33 4 92416795
Email olivia.keita-perse@chpg.mc
Status Recruiting
Phase N/A
Start date February 4, 2020
Completion date October 1, 2021

See also
  Status Clinical Trial Phase
Active, not recruiting NCT06057727 - Behavioral Economics to Improve Flu Vaccination Using EHR Nudges N/A
Completed NCT03694808 - FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care Phase 4
Completed NCT06385821 - A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus Phase 3
Completed NCT01440205 - Licensing Flu Shot Study N/A
Terminated NCT00769002 - PET-CT Scans in Healthy Volunteers After Flu Vaccination N/A
Completed NCT03308825 - Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines Phase 4
Completed NCT03189537 - Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections Phase 3
Completed NCT01484522 - Laboratory Study of Licensed H1N1 Influenza Vaccines in HIV-1 Perinatally Infected Children and Youth N/A
Completed NCT03344029 - Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years Phase 4
Completed NCT01459952 - A Double-blind, Randomised, Parallel Group,Comparative Study With Rose-hip Liquid and Placebo Given to Healthy Volunteers in the Winter Season Aiming to Evaluate the Occurences of Flu and Catching a Cold Phase 3
Completed NCT00644540 - Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study Phase 2
Recruiting NCT06158659 - Improved Immunology Outcomes Associated With Lactoferrin Fortified With HMO in Infant Formula N/A
Completed NCT05417997 - Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients Phase 3
Completed NCT01389518 - Efficacy and Safety of Paracetamol, Chlorpheniramine and Phenylephrine in the Treatment of Common Cold and Flu Syndrome Phase 3
Completed NCT02822105 - Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers Phase 1
Withdrawn NCT02037282 - A Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy Subjects Phase 1
Completed NCT03293979 - Alere i FluA*B Biologic Test Relocated in Emergency Service for Flu Diagnosis
Completed NCT04153331 - Burden of Influenza at Emergency Department Level : BIED N/A
Not yet recruiting NCT05473325 - Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)
Completed NCT01533220 - Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal Phase 3